Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
364.58
-21.61 (-5.60%)
At close: Aug 20, 2026, 4:00 PM EDT
366.01
+1.43 (0.39%)
Pre-market: Aug 21, 2026, 7:28 AM EDT
Praxis Precision Medicines Employees
Praxis Precision Medicines had 168 employees as of December 31, 2025. The number of employees increased by 52 or 44.83% compared to the previous year.
Employees
168
Change (1Y)
52
Growth (1Y)
44.83%
Revenue / Employee
n/a
Profits / Employee
-$2,018,607
Market Cap
10.18B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 168 | 52 | 44.83% | 168 | 0 |
| Dec 31, 2024 | 116 | 34 | 41.46% | 116 | 0 |
| Dec 31, 2023 | 82 | -27 | -24.77% | 82 | 0 |
| Dec 31, 2022 | 109 | -30 | -21.58% | 109 | 0 |
| Dec 31, 2021 | 139 | 72 | 107.46% | 139 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Ionis Pharmaceuticals | 1,480 |
| Axsome Therapeutics | 1,346 |
| Cytokinetics | 673 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 273 |
| Summit Therapeutics | 265 |
| Apogee Therapeutics | 261 |
PRAX News
- 1 hour ago - Praxis Precision price target raised to $575 from $470 at Goldman Sachs - TheFly
- 3 days ago - Praxis Precision price target raised to $945 from $765 at Raymond James - TheFly
- 13 days ago - Praxis Precision price target raised to $462 from $449 at RBC Capital - TheFly
- 13 days ago - Praxis Precision price target raised to $514 from $400 at Baird - TheFly
- 14 days ago - Praxis Precision price target raised to $362 from $323 at Wells Fargo - TheFly
- 14 days ago - Praxis Precision Medicines Earnings Call Transcript: Q2 2026 - Transcripts
- 14 days ago - Praxis Precision Medicines Earnings release: Q2 2026 - Filings
- 14 days ago - Praxis Precision Medicines Quarterly report: Q2 2026 - Filings